SEARCH

SEARCH BY CITATION

References

  • 1
    SwerdlowSH,CampoE,HarrisNL, et al., editors. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
  • 2
    Stein H,Delsol G,Pileri SA, et al. Classical Hodgkin lymphoma, introduction. In: SwerdlowSH,CampoE,HarrisNL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp 326329.
  • 3
    Raphael M,Said J,Borish B, et al. Lymphomas associated with HIV infection. In: SwerdlowSH,CampoE,HarrisNL, et al., editors.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. pp 340342.
  • 4
    Swerdlow SH,Webber SA,Chadburn A,Ferry JA. Post-transplant lymphoproliferative disorders. In: SwerdlowSH,CampoE,HarrisNL, et al., editors.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008, pp 343349.
  • 5
    Jaffe ES,Stein H,Swerdlow SH, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In: SwerdlowSH,CampoE,HarrisNL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp 267268.
  • 6
    Gaulard P,Swerdlow SH,Harris SH, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: SwerdlowSH,CampoE,HarrisNL, et al., editors.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008, pp 350351.
  • 7
    Carbone A,Gloghini A,Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999; 93: 23192326.
  • 8
    Carbone A,Gloghini A,Dotti G. EBV-associated lymphoproliferative disorders: Classification and treatment. Oncologist 2008; 13: 577585.
  • 9
    Grogg KL,Miller RF,Dogan A. HIV infection and lymphoma. J Clin Pathol 2007; 60: 13651372.
  • 10
    Carbone A,Gloghini A,Serraino D,Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009; 4: 310.
  • 11
    Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 2007; 14: 189194.
  • 12
    Carbone A,Gloghini A,Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780789.
  • 13
    Falini B,Fizzotti M,Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 20842092.
  • 14
    Carbone A,Gloghini A,Aldinucci D, et al. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 2002; 117: 366372.
  • 15
    Gloghini A,Carbone A. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int J Cancer 2007; 120: 27532754.
  • 16
    Skinnider BF,Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 42834297.
  • 17
    Aldinucci D,Lorenzon D,Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumour cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769776.
  • 18
    Fischer M,Juremalm M,Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003; 107: 197201.
  • 19
    Niens M,Visser L,Nolte IM, et al. Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22. Br J Haematol 2008; 140: 527536.
  • 20
    Van den Berg A,Visser L,Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999; 154: 16851691.
  • 21
    Hanamoto H,Nakayama T,Miyazato H, et al. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 2004; 164: 9971006.
  • 22
    Baumforth KR,Birgersdotter A,Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008; 173: 195204.
  • 23
    Shimabukuro-Vornhagen A,Haverkamp H,Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: Clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 2005; 23: 57395745.
  • 24
    Marshall NA,Culligan DJ,Tighe J, et al. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol 2007; 35: 596604.
  • 25
    Maggio E,van den Berg A,Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002; 13: 5256.
  • 26
    Uchihara JN,Krensky AM,Matsuda T, et al. Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1. Int J Cancer 2005; 114: 747755.
  • 27
    Spitz MR,Sider JG,Johnson CC. Ethnic patterns of Hodgkin's disease incidence among children and adolescents in the United States, 1973–82. J Natl Cancer Inst 1986; 76: 235239.
  • 28
    Cleary SF,Link MP,Donaldson SS. Hodgkin's disease in the very young. Int J Radiat Oncol Biol Phys 1994; 28: 7783.
  • 29
    Jarrett RF. Viruses and Hodgkin's lymphoma. Ann Oncol 2002; 13( Suppl 1): 2329.
  • 30
    Alexander FE,Jarrett RF,Lawrence D. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: Prior infection by EBV and other agents. Br J Cancer 2000; 82: 11171121.
  • 31
    Hjalgrim H,Askling J,Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 13241332.
  • 32
    Thorley-Lawson DA,Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 13281337.
  • 33
    Donaldson SS. Pediatric Hodgkin's disease—Up, up, and beyond. Int J Radiat Oncol Biol Phys 2002; 54: 18.
  • 34
    Smith RS,Chen Q,Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003; 21: 20262033.
  • 35
    Ruhl U,Albrecht M,Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 Trial. Int J Radiat Oncol Biol Phys 2001; 51: 12091218.
  • 36
    Landman-Parker J,Pacquement H,Leblanc T, et al. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy: Results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000; 18: 15001507.
  • 37
    Laskar S,Gupta T,Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 2004; 22: 6268.
  • 38
    Arya L,Dinand V,Thavaraj V, et al. Hodgkin's disease in Indian children: Outcome with chemotherapy alone. Pediatr Blood Cancer 2006; 46: 2634.
  • 39
    Hakvoort-Cammel FG,Buitendijk S,van den Heuvel-Eibrink M,Hählen K. Treatment of pediatric Hodgkin disease avoiding radiotherapy: Excellent outcome with the Rotterdam-HD-84-Protocol. Pediatr Blood Cancer 2004; 43: 816.
  • 40
    Nachman J,Sposto R,Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 37653771.
  • 41
    Donaldson SS,Link MP,Weinstein RJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low risk Hodgkin's disease. J Clin Oncol 2007; 25: 332337.
  • 42
    Schellong G,Potter R,Brämswig J, et al. High cure rates and reduced long term toxicity in pediatric Hodgkin's disease: The German-Austrian Multicenter Trial DAL-HD-90.The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999; 17: 37363744.
  • 43
    Schwartz CL,Constine LS,Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 2009; 114: 20512059.
  • 44
    Clinical Trials.gov [a service of the US National Institutes of Health]. Chemotherapy with or without additional chemotherapy and/or radiation therapy in treating children with newly diagnosed Hodgkin's disease (NCT00025259) [online]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00025259?term= NCT00025259&rank=1 Accessed August 16, 2010.
  • 45
    Hudson MM,Krasin M,Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004; 22: 45414550.
  • 46
    Kelly KM,Hutchinson RJ,Sposto R, et al. Feasibility of upfront dose intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: Preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol 2002; 13( Suppl 1): 107111.
  • 47
    Verdecchia A,Francisci S,Brenner H, et al. Recent cancer survival in Europe: A 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784796.
  • 48
    Brenner H,Gondos A,Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008; 111: 29772983.
  • 49
    Bosetti C,Levi F,Ferlay J, et al. The recent decline in mortality from Hodgkin lymphomas in central and eastern Europe. Ann Oncol 2009; 20: 767774.
  • 50
    Aleman BM,van den Belt-Dusebout AW,Klokman WJ, et al. Longterm cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 34313439.
  • 51
    Brusamolino E,Baio A,Orlandi E, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res 2006; 12: 64876493.
  • 52
    Noordijk EM,Carde P,Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 31283135.
  • 53
    Ferme C,Eghbali H,Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 19161927.
  • 54
    Engert A,Schiller P,Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 36013608.
  • 55
    Bonadonna G,Bonfante V,Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 2004; 22: 28352841.
  • 56
    Engert A,Pluetschow A,Eich HT, et al. Combined modality treatment of two or four cycles of ABVD followed by IFRT in the treatment of patients with early stage Hodgkin's lymphoma: Update interim analysis of the randomised HD10 study of the German Hodgkin study group (GHSG). Blood 2005; 106: 750a.
  • 57
    Diehl V,Brillant C,Engert A, et al. Recent interim analysis of the HD11 trial of the GHSG: Intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma. Blood 2005; 106: 240a241a.
  • 58
    Ferme C,Divine M,Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-U trial. Blood 2005; 106: 240a.
  • 59
    Rueda Dominguez A,Marquez A,Gumá J, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: Results after 7 years of a prospective study. Ann Oncol 2004; 15: 17981804.
  • 60
    Straus DJ,Portlock CS,Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 34833489.
  • 61
    Meyer RM,Gospodarowicz MK,Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 46344642.
  • 62
    Eghbali H,Brice P,Creemers GY, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-F trial. Blood 2005: 106: 240a.
  • 63
    DeVita VTJr,Simon RM,Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587595.
  • 64
    Longo DL,Young RC,Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 12951306.
  • 65
    Santoro A,Bonadonna G,Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 2737.
  • 66
    Bonadonna G,Valagussa P,Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104: 739746.
  • 67
    Somers R,Carde P,Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279287.
  • 68
    Viviani S,Bonadonna G,Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 1996; 14: 14211430.
  • 69
    Connors JM,Klimo P,Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy—Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997; 15: 16381645.
  • 70
    Canellos GP,Anderson JR,Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 14781484.
  • 71
    Duggan DB,Petroni GR,Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 2003; 21: 607614.
  • 72
    Johnson PW,Radford JA,Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23: 92089218.
  • 73
    Aleman BM,Raemaekers JM,Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 23962406.
  • 74
    Fermé C,Mounier N,Casasnovas O, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 107: 46364642.
  • 75
    Eich HT,Gossmann A,Engert A, et al. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma—Analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2007; 69: 11871192.
  • 76
    Federico M,Luminari S,Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805811.
  • 77
    Gianni AM,Rambaldi A,Pulsoni A, et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma: A randomized trial of the Michelangelo,GITIL and IIL cooperative groups. J Clin Oncol 2008; 26:Abs. 8506.
  • 78
    Diehl V,Franklin J,Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 23862395.
  • 79
    Federico M,Bellei M,Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21: 23202325.
  • 80
    Engert A,Diehl V,Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 Study. J Clin Oncol 2009; 27: 45484554.
  • 81
    Carella AM,Bellei M,Brice P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: Long-term results. Haematologica 2009; 94: 146148.
  • 82
    Carbone A,Gloghini A,Aiello A, et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol 2010; 41: 621631.
  • 83
    Zinzani PL,Martelli M,Magagnoli M, et al. Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood 1998; 92: 790794.
  • 84
    Calvo KR,Traverse-Glehen A,Pittaluga S,Jaffe ES. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: Implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol 2004; 11: 227238.
  • 85
    García JF,Mollejo M,Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005; 47: 101110.
  • 86
    Engert A,Ballova V,Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 50525060.
  • 87
    Jarrett RF,Stark GL,White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study. Blood 2005; 106: 24442451.
  • 88
    Diepstra A,van Imhoff GW,Schaapveld M, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009; 27: 38153821.
  • 89
    Levis A,Depaoli L,Urgesi A, et al. Probability of cure in elderly Hodgkin's disease patients. Haematologica 1994; 79: 4654.
  • 90
    Weekes CD,Vose JM,Lynch JC, et al. Hodgkin's disease in the elderly: Improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002; 20: 10871093.
  • 91
    Macpherson N,Klasa RJ,Gascoyne R, et al. Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): A phase II study. Leuk Lymphoma 2002; 43: 13951402.
  • 92
    Kim HK,Silver B,Li S, et al. Hodgkin's disease in elderly patients (≥60): Clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys 2003; 56: 556560.
  • 93
    van Spronsen DJ,Janssen-Heijnen ML,Breed WP,Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993–1996. Ann Hematol 1999; 78: 315319.
  • 94
    Diaz-Pavon JR,Cabanillas F,Majlis A,Hagemeister FB. Outcome of Hodgkin's disease elderly patients. Hematol Oncol 1995; 13: 1924.
  • 95
    Levis A,Depaoli L,Bertini M, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996; 81: 450456.
  • 96
    Specht L,Nissen NI. Hodgkin's disease and age. Eur J Haematol 1989; 43: 127135.
  • 97
    Erdkamp FL,Breed WP,Bosch LJ, et al. Hodgkin disease in the elderly. A registry-based analysis. Cancer 1992; 70: 830834.
  • 98
    Stark GL,Wood KM,Jack F, et al. Hodgkin's disease in the elderly: A population-based study. Br J Haematol 2002; 119: 432440.
  • 99
    Enblad G,Glimelius B,Sundström C. Treatment outcome in Hodgkin's disease in patients above the age of 60: A population-based study. Ann Oncol 1991; 2: 297302.
  • 100
    Taylor PR,Angus B,Owen JP,Proctor SJ. Hodgkin's disease: A population-adjusted clinical epidemiology study (PACE) of management at presentation. Northern Region Lymphoma Group. QJM 1998; 91: 131139.
  • 101
    Klimm B,Diehl V,Engert A. Hodgkin's lymphoma in the elderly: A different disease in patients over 60. Oncology (Williston Park) 2007; 21: 982990.
  • 102
    Levis A,Anselmo AP,Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004; 15: 123128.
  • 103
    Landgren O,Algernon C,Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003; 88: 438444.
  • 104
    Ballova V,Ruffer JU,Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 2005; 16: 124131.
  • 105
    Extermann M,Aapro M,Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241252.
  • 106
    Nakamura S,Jaffe ES,Swerdlow SH. EBV positive diffuse large B-cell lymphoma of the elderly in lymphoproliferative diseases associated with primary immune disorders. In: SwerdlowSH,CampoE,HarrisNL, et al., editors.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. pp 243244.
  • 107
    Oyama T,Yamamoto K,Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res 2007; 13: 51245132.
  • 108
    Shimoyama Y,Asano N,Kojima M, et al. Age-related EBV-associated B-cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entity. Pathol Int 2009; 59: 835843.
  • 109
    Asano N,Yamamoto K,Tamaru J, et al. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: Comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 2009; 113: 26292636.
  • 110
    Murase T,Fujita A,Ueno H, et al. A case of age-related EBV-associated B-cell lymphoproliferative disorder metachronously showing two distinct morphologic appearances, one of a polymorphic disease resembling classical Hodgkin lymphoma, and the other of a large-cell lymphoma. Int J Hematol 2009; 89: 8085.
  • 111
    Serraino D,Boschini A,Carrieri P, et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000; 14: 553559.
  • 112
    Franceschi S,Dal Maso L,Pezzotti P, et al.Cancer and AIDS Registry Linkage Study. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986–1998. J Acquir Immune Defic Syndr 2003; 34: 8490.
  • 113
    Clifford GM,Rickenbach M,Lise M, et al. Hodgkin lymphoma in the Swiss HIV cohort study. J Clin Oncol 2009; 113: 57375742.
  • 114
    Biggar RJ,Jaffe ES,Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108: 37863791.
  • 115
    Powles T,Robinson D,Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884890.
  • 116
    Levine AM. Hodgkin lymphoma: To the HAART of the matter. Blood 2006; 108: 3630.
  • 117
    Tirelli U,Errante D,Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995; 13: 17581767.
  • 118
    Vaccher E,Spina M,Talamini R, et al. Improvement of systemic human immunodeficiency virus-related NHL in the era of HAART. Clin Infect Dis 2009; 37: 15561564.
  • 119
    Chimienti E,Spina M,Gastaldi R, et al. Clinical characteristics and outcome of 290 patients (pts) with Hodgkin's disease and HIV infection (HD-HIV) in pre and HAART (highly active antiretroviral therapy) era. Ann Oncol 2008; 19: iv136; abs 168.
  • 120
    Errante D,Tirelli U,Gastaldi R, et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. Cancer 1994; 73: 437444.
  • 121
    Errante D,Gabarre J,Ridolfo AL, et al. Hodgkin's disease in 35 patients with HIV infection: An experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol 1999; 10: 189195.
  • 122
    Levine AM,Li P,Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony-stimulating factor CSF in HIV infected patients with newly diagnosed Hodgkin's disease: A prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24: 444450.
  • 123
    Hasenclever D,Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 15061514.
  • 124
    Spina M,Gabarre J,Rossi G, et al. Stanford V and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection. Blood 2002; 100: 19841988.
  • 125
    Hartmann P,Rehwald U,Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003; 14: 15621569.
  • 126
    Xicoy B,Ribera JM,Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92: 191198.
  • 127
    Spina M,Rossi G,Antinori A, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV). Ann Oncol 2008; 19: iv152; abs227.
  • 128
    Krishnan A,Molina A,Zaia J, et al. Durable remission with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105: 874878.
  • 129
    Serrano D,Carrion R,Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 2005; 33: 487494.
  • 130
    Re A,Michieli M,Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: Long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114: 13061313.
  • 131
    Hayashi RJ,Kraus MD,Patel AL, et al. Post-transplant lymphoproliferative disease in children: Correlation of histology to clinical behaviour. J Pediatr Hematol Oncol 2001; 23: 1418.
  • 132
    Midthum D,McDougall J,Peters S,Scott JP. Medical management and complications in the lung transplant recipient. Mayo Clin Proc 1997; 72: 175184.
  • 133
    Rohr JC,Wagner HJ,Lauten M, et al. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant 2008; 12: 426431.
  • 134
    Knight JS,Tsodikov A,Cibrik DM, et al. Lymphoma after solid organ transplantation: Risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009; 27: 33543362.
  • 135
    Adams H,Campidelli C,Dirnhofer S, et al. Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. Expert Opin Ther Targets 2009; 13: 11371145.
  • 136
    Bierman PJ,Vose JM,Langnas AN, et al. Hodgkin's disease following solid organ transplantation. Ann Oncol 1996; 7: 265270.
  • 137
    Dharnidharka VR,Douglas VK,Hunger SP,Fennell RS. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant 2004; 8: 8790.
  • 138
    Krishnamurthy S,Hassan A,Frater JL, et al. Pathologic and clinical features of Hodgkin lymphoma-like posttransplant lymphoproliferative disease. Int J Surg Pathol 2010; 18: 278285.
  • 139
    Garnier JL,Lebranchu Y,Dantal J, et al. Hodgkin's disease after transplantation. Transplantation 1996; 61: 7176.
  • 140
    Goyal RK,McEvoy L,Wilson DB. Hodgkin's disease after renal transplantation: I. Childhood. J Pediatr Hematol Oncol 1996; 18: 392395.
  • 141
    Pitman SD,Huang Q,Zuppan CW, et al. Hodgkin's lymphoma-like posttransplantation lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006; 30: 470476.
  • 142
    Pham PT,Wilkinson AH,Gritsch HA, et al. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with post-transplant lymphoproliferative disease. Transplant Proc 2002; 34: 11781181.
  • 143
    Hasserjian RP,Chen S,Perkins SL, et al. Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol 2009; 22: 15321540.
  • 144
    Kamel OW,van de Rijn M,Weiss LM, et al. Brief report: Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 13171321.
  • 145
    Diehl V,Stein H,Hummel M, et al. Hodgkin's lymphoma: Biology and treatment strategies for primary refractory and relapsed disease. Hematology Am Soc Hematol Program 2003; 1: 225247.
  • 146
    Josting A,Nogová L,Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23: 15221529.
  • 147
    Tzankov A,Krugmann J,Fend F, et al. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: A clinicopathological study of 119 cases. Clin Cancer Res 2003; 9: 13811386.
  • 148
    Molot RJ,Mendenhall NP,Barré DM,Braylan RC. The clinical relevance of L26, a B-cell-specific antibody in Hodgkin's disease. Am J Clin Oncol 1994; 17: 185188.
  • 149
    Donnelly GB,Filippa D,Moskowitz CH, et al. Increased treatment failure in patients with CD20 positive classic Hodgkin disease (HD). Blood 1999; 94: 598A.
  • 150
    Rassidakis GZ,Medeiros LJ,Viviani S, et al. CD20 expression in Hodgkin disease and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome. J Clin Oncol 2002; 20: 12781287.
  • 151
    Portlock CS,Donnelly GB,Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol 2004; 125: 701708.
  • 152
    Canioni D,Deau-Fischer B,Taupin P, et al. Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: A study of 59 cases. PLoS One 2009; 4: e6341.
  • 153
    Linch DC,Winfield D,Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 10511054.
  • 154
    Schmitz N,Pfistner B,Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 20652071.
  • 155
    Brice P,Bouabdallah R,Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry. Société Francaise de Greffe de Moelle. Bone Marrow Transplant 1997; 20: 2126.
  • 156
    Josting A,Rudolph C,Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 16281635.
  • 157
    Moskowitz CH,Nimer SD,Zelenetz AD, et al. A 2-step comprehensive high-dose chemo-radiotherapy second-line program for relapsed and refractory Hodgkin's disease: Analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616623.
  • 158
    Santoro A,Magagnoli M,Spina M,. et al. Ifosfamide, gemcitabine, and vinorelbine (IGEV): A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92: 3541.
  • 159
    Balsalobre P,Díez-Martín JL,Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009; 27: 21922198.
  • 160
    Anderson JE,Litzow MR,Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 1993; 11: 23422350.
  • 161
    Gajewski JL,Phillips GL,Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 142: 7278.
  • 162
    Akpek G,Ambinder RF,Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 43144321.
  • 163
    Peniket AJ,Ruiz de Elvira MC,Taghipour G, et al.European Bone Marrow Transplantation (EBMT) Lymphoma Registry. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667678.
  • 164
    Robinson SP,Goldstone AH,Mackinnon S, et al. Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 43104316.
  • 165
    Peggs KS,Hunter A,Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 19341941.
  • 166
    Anderlini P,Saliba R,Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2003; 35: 943951.
  • 167
    Alvarez I,Sureda A,Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish Prospective Cooperative Protocol. Biol Blood Marrow Transplant 2006; 12: 172183.